TickerTalks
Browse all tickers →
TickerTalks›$CI
CICI

Cigna Corporation

$CI·$75B·Medical - Healthcare Plans·Healthcare
$283.93+0.4%YTD-0.9%1Y-5.9%
Mentions · last 7 days
2026-08-24: 7 posts32
Price updated 3m ago·X counts updated 10d ago
CICI
$CICigna Corporation
$283.93+0.39%32 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CI, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersStalledAI verdict · as of 2026-08-21

The move has stalled — likely just drifts unless something new shows up.

Managed-care giant trading at a group-wide discount — cheap on the numbers, but the sector overhang won't lift on its own.

Cigna is one of the largest US health insurers and, through Evernorth/Express Scripts, one of the biggest pharmacy-benefit managers. The whole managed-care group has been under pressure on medical-cost inflation and PBM political risk, and CI's tape has flatlined even though its numbers keep printing beats.

  • Q2 EPS came in at $7.78 vs $7.60 consensus — the fourth straight beat, and the last four have all landed between 2-3% above the sell-side, showing CI is consistently guiding conservatively and delivering.
  • Trades at ~12x trailing earnings against the S&P at ~22x — a roughly 45% multiple discount to the market, with a 10% free-cash-flow yield that is unusual for a large-cap compounder.
  • On Aug 18, general counsel Nicole Jones sold $749K plus another $5.4M on Aug 4 after exercising options — a real cluster from a Section-16 officer, and the kind of signal that usually softens a bull argument even when the sales look pre-planned.
  • Sits at the 46th percentile of the 52-week range — the tape is genuinely stuck, not breaking either way.

What restarts the move is the Oct 29 Q3 print combined with clean 2027 guide — that's the market's read on whether medical-cost trend is finally under control. What sustains the stall is another quarter of the group headlines (UnitedHealth's cost issues, PBM legislation) drowning out CI's own execution.

Agrees with X sentimentThe X take agrees with the mechanics — Goldman's $352 target on a Buy rating is consistent with the 12x TTM multiple and the beat cadence, and Cigna's ongoing buyback (X's 'if investors don't buy the stock the company will' line) is real. The Nicole Jones sale cluster is the piece the crowd isn't foregrounding.

What to watch: Oct 29 Q3 earnings — Cigna's medical-loss ratio and 2027 guidance are the two numbers that decide whether the sector discount closes. Any additional Form 4 selling from named officers would harden the ceiling.

On the calendar: 2026-10-29 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-08-07

Cigna posters note Goldman raised its price target to $352 from $340 (Buy) and Barclays adjusted to $310 from $304 (Equalweight). ChatGPT's Rallies AI Arena portfolio increased its CI position to 65 shares — the AI portfolio is up 77%+ YTD. One poster describes CI as an existing long thesis with earnings power sustainable and 'if investors don't buy the stock the company will.' Peers CLOV and OSCR are cited as challengers to UNH/HUM/CI.

Read the AI verdict + X sentiment for $CI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large health insurer and pharmacy-benefits manager operating Evernorth (PBM/care) and Cigna Healthcare segments.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Plans sits in its cycle right now — and what that implies for $CI.

Medical - Healthcare Plans · Healthcare

Medical loss ratio trends are the central earnings variable; Medicaid redeterminations and ACA enrollment shifts are rebalancing member mix. Prior authorization practices face regulatory pressure that could weigh on cost control levers.

What this means for $CI

Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, p.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+17.6%YTD
+21.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
12.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
7.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
3.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
10.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
15.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
9.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$7.78$7.60+2.4%
Q1 2026Apr 30, 2026$7.79$7.60+2.5%
Q4 2025Feb 5, 2026$8.08$7.88+2.5%
Q3 2025Oct 30, 2025$7.83$7.64+2.5%
Next earningsThu, Oct 29·consensus EPS $7.46

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$68.5B+4.6%9.4%3.4%$6.30$864.0M
Q4 FY25$72.5B+10.4%7.7%3.0%$4.64$5.8B
Q3 FY25$69.7B+9.5%8.5%3.7%$7.02$3.1B
Q2 FY25$67.2B+11.1%11.7%3.6%$5.76$-2.2B

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$286.0B$281.7B – $290.2B$30.44$30.27 – $30.635
FY27$298.2B$292.0B – $306.7B$33.49$32.50 – $34.2112
FY28$315.6B$305.8B – $326.0B$36.98$29.79 – $44.1713
FY29$330.8B$324.0B – $336.8B$41.46$40.35 – $42.4412
FY30$335.9B$329.0B – $342.0B$46.32$45.09 – $47.426

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.57%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-0.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+1.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 262.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.325-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 18Nicole S JonesSee Remarks2.7K sh$749KSellAug 4Nicole S JonesSee Remarks19.4K sh$5.4MSellJun 12Jamie G KatesChief Accounting Officer899 sh$268KSellMay 12David CordaniCEO32.0K sh$9.2M
+ 19 other (14 awards · 5 exempts) in window

See when $CI insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 93
AI summary

Initial Form 3 ownership statement filed by Bryan Holgerson, a newly reportable officer or director at The Cigna Group, disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person effective July 1, 2026. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying officer or director role. No operational implications for the company.

3New insider — initial holdingsJul 93
AI summary

Initial Form 3 ownership statement filed by Adam Kautzner, a newly reportable officer or director at The Cigna Group, disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person effective July 1, 2026. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying officer or director role. No operational implications for the company.

3New insider — initial holdingsJul 93
AI summary

Initial Form 3 ownership statement filed by Jason Sadler, a newly reportable officer or director at The Cigna Group, disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person effective July 1, 2026. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying officer or director role. No operational implications for the company.

3New insider — initial holdingsJul 93
AI summary

Initial Form 3 ownership statement filed by Paul Sanford, a newly reportable officer or director at The Cigna Group, disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person effective July 1, 2026. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying officer or director role. No operational implications for the company.

3New insider — initial holdingsJul 93
AI summary

Initial Form 3 ownership statement filed by Matthew Perlberg, a newly reportable officer or director at The Cigna Group, disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person effective July 1, 2026. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying officer or director role. No operational implications for the company.

8-KPress release / Reg FDMay 138-K — Item 7.01: Press release / Reg FD
AI summary

CI (CI) disclosed a dividend declaration or distribution announcement under 8-K Item 7.01. The dividend is $30.35 per share. Dividend announcements are material events that directly impact shareholder returns and signal management's view of the company's financial health and cash flow sustainability. Investors monitor dividend continuity and growth as indicators of long-term financial strength.

8-KShareholder voteApr 278-K — Item 5.07: Shareholder vote
AI summary

CI (CI) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an advisory say-on-pay resolution, ratification of the independent auditor, shareholder proposals. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

3New insider — initial holdingsApr 33
+ 10 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Here's Why Cigna (CI) is a Strong Value Stockzacks.com·3d agoBeacon Pointe Advisors LLC Buys Shares of 39,957 Cigna Group $CIdefenseworld.net·5d agoCan Cigna's Smart Coverage Help Close Health-Cost Gaps?zacks.com·7d agoBeneath the Headlines: An Economy in Transition, Not in Troubleetftrends.com·8d agoCigna Healthcare Connects Medical and Supplemental Benefits To Help People Better Manage Unexpected Health Costsprnewswire.com·8d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Medical - Healthcare Plans

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OSCR$UNH$CVS$CLOV$HUM$CNC$ELV$MOH
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport